Cosmo Godino։ Aortic Stenosis Is More Than a Valve Disease
Cosmo Godino, Medical Doctor at San Raffaele Hospital, shared a post on LinkedIn:
”For years, we have defined aortic stenosis using rigid cut-offs: AVA less than 1 cm²Mean gradient greater than 40 mmHg.
But clinical practice teaches us something different.
Some patients with ‘only’ moderate aortic stenosis are highly symptomatic, develop pulmonary hypertension, myocardial damage, heart failure, and experience major cardiovascular events.
Meanwhile, others with similar valve parameters remain relatively stable.
Why?
Because aortic stenosis is not just a valve disease.
The impact on the myocardium, filling pressures, pulmonary circulation, renal function, associated valvular disease and overall patient complexity may matter more than the valve gradient itself.
Our recently published SPARK score moves in this direction: a broader and more tailored evaluation of patients with moderate AS.
Medicine is changing.
We need to move beyond old and limited cut-offs toward a more patient-centered and individualized approach.
Because we should treat patients – not numbers.”

Stay updated with Hemostasis Today.
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics
-
Nov 14, 2026, 23:33Alexandros Makis: Exploring Vascular Mechanisms and Therapeutic Targets in β-Thalassemia